Skip to main content

Table 1 Characteristics of PLWH enrolled in the study (N = 299)

From: Factors associated with oxidative stress in virologically suppressed people living with HIV on long-term antiretroviral therapy

 

Whole population n = 299

Sex, n (%)

 

 Male

226 (75.6)

 Female

73 (24.4)

Age,years,median (IQR)

52 (44–60)

Caucasian,n (%)

269 (90.0)

Risk factor,n (%)

 

 MSM

138 (46.2)

 Heterosexual

118 (39.5)

 PWID

15 (5.0)

 Unknown/others

28 (9.3)

Time since HIV diagnosis,years,median (IQR)

12.0 (7.3–20.1)

Time on ART,years,median (IQR)

10.6 (7.2–15.7)

BMI,median (IQR)

25.0 (21–28)

Smoking habitsa, n (%)

154 (51.5)

Currently smoking

152 (50.8)

Quit smoking

2 (0.67)

Alcohol useb, n (%)

133 (44.5)

CD4 cell count nadir,cells/mm3, median (IQR)

214 (72–340)

Zenith HIV-RNA,Log10copie/mL,median (IQR)

5.04 (4.46–5.46)

CD4 cell count,cells/mm3, median (IQR)

690 (491–874)

CD8 cell count,cells/mm3, median (IQR)

662 (503–878)

CD4/CD8 ratio,median (IQR)

1.01 (0.76–1.38)

HIV-RNA TND (0 copy/mL),n (%)

292 (97.7)

Past AIDS-defining events,(CDC C),n (%)

78 (26.1)

History of cardiovascular diseasesc, n (%)

48 (16.1)

History of cancerd, n (%)

30 (10.0)

Co-infection,n (%)

 

HCV Co-infectione

37 (12.4)

HBV Co-infectionf

5 (1.7)

Comorbidities,n (%)

 

 Hypertension

44 (14.7)

 Diabetes

16 (5.4)

 Psychiatric

44 (14.7)

ART,n (%)g

 

Triple regimen

156 (52.8)

2NRTIs + INSTI

98 (63.3)

 FTC/TAF/BIC

76 (77.5)

 FTC/TAF + DTG

14 (14.3)

 FTC/TAF + RGV

8 (8.2)

2NRTIs + NNRTI

43 (27.2)

 FTC/TAF/RPV

25 (58.1)

 3TC/TDF/DOR

18 (41.9)

2NRTIs + PI/b

15 (9.5)

 FTC/TAF/DRV/COBI

 

Dual regimen

141 (47.2)

NRTI + INSTI

133 (95.0)

 3TC/DTG

133 (100.0)

NRTI + PI/b

8 (5.0)

 3TC + DRV/COBI

8 (100.0)

Concomitant drugs,n (%)

 

Statins

31 (10.4)

Vitamins

67 (22.4)

Lipid Nutritional Supplements

50 (16.7)

NSAIDs

7 (2.3)

Lipid profile,median (IQR)

 

 Cholesterol,mg/dL

182 (154–205)

 Triglycerides,mg/dL

104 (74–151)

 HDL,mg/dL

46 (39–54)

Previous bliph, n (%)

121 (40.5)

Previous failurei, n (%)

85 (28.4)

Time since last detectable viral load (≥ 50cps/mL),years,median (IQR)

7.9 (5.0-12.1)

Cumulative time with viral load < 50cps/mL,years,median (IQR)

9.04 (5.9–13.2)

  1. Abbreviations BMI: Body mass index; PWID: people who inject drugs; MSM: Men who have sex with men; ART: Antiretroviral therapy; HCV: Hepatitis C; HBV: Hepatitis B; THN: target not detected; NRTIs: Nucleoside reverse transcriptase inhibitors; NNRTIs; Non-nucleoside reverse transcriptase inhibitors; INSTIs: Integrase Inhibitors; PI: Protease Inhibitor. NSAIDs: Non-steroid anti-inflammatory drugs
  2. a An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes and who had quit smoking in the previous 6 months. All the current smokers smoke ≥ 10 cigarettes per day; b ≥2 alcoholic unit/day; c Includes cardiomyopathy, ischaemic stroke and myocardial infarction; d Previous non-aids related tumor. e Defined as HCV RNA detected. f Defined as HBcAb positive. g Two PLWH were on non-conventional ART. h Defined as a single HIV-RNA values between 50–999 copies/mL. i Defines as single HIV-RNA value equal to1,000 or at least two consecutive values between 50 − 1,000 copies/mL
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us